Loading quotes...

Forecast

The analysts' average price target is €109.02 (+219.52%). The median is €125.80 (+268.70%).

Buy	22
Hold	6
Sell	5

News Go to news feed

Nektar outlines Phase 3 rezpeg trials and $1.02bn cash runway into 2028

Nektar is enrolling Phase 3 trials for rezpegaldesleukin (rezpeg) in atopic dermatitis and alopecia areata, with top-line atopic dermatitis data expected mid-2028 and a potential BLA submission in 2029. The company reported a $1.02 billion cash balance that management says funds operations into 2028, while operating losses widened and R&D spending is guided to $210–230 million for the year. Nektar raised $373.8 million in April through a public offering, faces a federal jury trial in September 2026, and carries elevated short interest as investors wait for pivotal data. » More on finance.yahoo.com
Nektar beats Q2 EPS forecast, revenue slightly below expectations and shares fall after hours

Nektar reported an adjusted loss of $1.23 per share for Q2, beating the consensus estimate of $2.00, while revenue of $10.13 million came in just below expectations. The company ended the quarter with $1.02 billion in cash and investments and expects those funds to last into the third quarter of 2028. Nektar is advancing lead candidate REZPEG in Phase III trials for atopic dermatitis and alopecia areata; key Phase III data for dermatitis are expected in mid-2028. Despite the earnings beat, the stock fell after hours as investors weighed the revenue miss, the long approval timeline and valuation risks. » More on de.investing.com
Nektar Therapeutics focused on immunology with REZPEG and more than $1 billion in liquidity

Nektar Therapeutics is concentrating on developing and out-licensing drug candidates, with lead compound REZPEG at the center for targeted immune modulation. REZPEG targets large markets such as atopic dermatitis and alopecia areata. With a liquidity reserve of more than $1 billion, the company is financially positioned to continue clinical research through at least 2028. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Nektar Therapeutics has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Nektar Therapeutics had revenue of €8.88M and net profit of -€35.59M

(EUR)	June 2026	YoY
Revenue	8.88M	6.37%
Gross profit	8.88M	6.37%
Net profit	-35.59M	0.86%
EBITDA	-36.88M	28.64%

Fundamentals

Metric	Value
Market capitalization	€959.45M
Number of shares	28.69M
52-week high/low	€97.94 - €30.01
Dividends	No
Beta	1.15
P/E ratio	-5.56
PEG ratio	-0.58
P/B ratio	1.36
P/S ratio	19.56

Company profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Name	Nektar Therapeutics
CEO	Howard W. Robin
Headquarters	San Francisco, ca USA
Website	nektar.com
Sector	Health Care
Industry	Biotechnology
IPO	05/03/1994
Employees	63